Logo smallSearch
Tydzień Pacjencki

Chronic lymphocytic leukemia (CLL) patients are still awaiting access to treatment

MedExpress Team


Published May 11, 2022 10:49

Chronic lymphocytic leukemia (CLL) patients are still awaiting access to treatment - Header image
Fot. Getty Images/iStockphoto
The number of newly diagnosed blood cancers in adults and children in Poland is approx. 9 thousand. annually, which accounts for approx. 5.5% of all malignant neoplasms in our country. The group of people diagnosed with these cancers is very wide, and the risk of developing the disease clearly increases over the age of 65. On May 28, we will celebrate the World Blood Cancer Day, so today we would like to remind you of the urgent needs of patients struggling with these diseases. The more so that at the beginning of the year, the HematoKoalicja report was presented, which presented the situation of hemato-oncological patients in Poland - their needs and problems as well as solutions that will help improve the situation of patients with blood cancers.

Chronic lymphocytic leukemia (CLL) is a blood cancer characterized by an excessive accumulation of abnormal, monoclonal B lymphocytes. People over the age of 65 are particularly at risk, although approximately 10-15% of patients are under 50 years of age. In the vast majority of cases, it is an incurable disease, and the aims of therapy are to control disease progression, extend life and improve its quality.

As indicated in the guidelines, only BTK inhibitors (akalabrutinib, ibrutinib) fully meet the therapeutic needs of the entire group at high risk of progression. In the case of refractory/recurrent CLL, the use of new targeted therapies is recommended, while immunoch...

Content locked

To gain access to the complete English section of the, kindly reach out to us at [email protected].

If you already have an account, please log in

Similar articles

Tydzień Pacjencki

Medexpress special publisher: Jacek Hołub

May 13, 2022
May 11, 2022
Tydzień Pacjencki

Medexpress special publisher: Sebastian Gawlik

April 25, 2022